AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$7.41 USD
+0.42 (6.01%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $7.24 -0.17 (-2.29%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.41 USD
+0.42 (6.01%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $7.24 -0.17 (-2.29%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
Zacks News
AngioDynamics (ANGO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 44.44% and 3.15%, respectively, for the quarter ended November 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why AngioDynamics (ANGO) Outpaced the Stock Market Today
by Zacks Equity Research
The latest trading day saw AngioDynamics (ANGO) settling at $7.63, representing a +1.87% change from its previous close.
AngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
AngioDynamics (ANGO) closed at $6.91 in the latest trading session, marking a -0.72% move from the prior day.
AngioDynamics (ANGO) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
AngioDynamics (ANGO) closed the most recent trading day at $6.77, moving -1.31% from the previous trading session.
CVRx (CVRX) Moves 7.1% Higher: Will This Strength Last?
by Zacks Equity Research
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AngioDynamics (ANGO) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the most recent trading session, AngioDynamics (ANGO) closed at $6.74, indicating a -0.15% shift from the previous trading day.
AngioDynamics (ANGO) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
AngioDynamics (ANGO) closed the most recent trading day at $6.85, moving +1.33% from the previous trading session.
AngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the latest trading session, AngioDynamics (ANGO) closed at $6.86, marking a -1.15% move from the previous day.
AngioDynamics (ANGO) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, AngioDynamics (ANGO) stood at $6.21, denoting a +0.65% change from the preceding trading day.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2024.
AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 14.29% and 1.32%, respectively, for the quarter ended August 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics (ANGO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AngioDynamics (ANGO) closed at $7.02 in the latest trading session, marking a -0.71% move from the prior day.
Avid Bioservices (CDMO) Reports Break-Even Earnings for Q1
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 100% and 10.96%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AngioDynamics (ANGO) closed at $8.15, marking a +1.88% move from the previous day.
AngioDynamics (ANGO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AngioDynamics (ANGO) closed the most recent trading day at $8.76, moving -1.35% from the previous trading session.
AngioDynamics (ANGO) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
AngioDynamics (ANGO) closed at $8.58 in the latest trading session, marking no change from the prior day.
AngioDynamics' (ANGO) New FDA Recognition to Boost Treatment
by Zacks Equity Research
The FDA's grant of the Breakthrough Device designation for AngioDynamics' (ANGO) AngioVac is likely to remove thrombus and embolic material and minimize blood loss via blood recirculation.
AngioDynamics (ANGO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, AngioDynamics (ANGO) closed at $8.34, marking a +1.46% move from the previous day.
AngioDynamics (ANGO) Q4 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in fourth-quarter fiscal 2023.
AngioDynamics (ANGO) Lags Q4 Earnings Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -33.33% and 0.37%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AngioDynamics' (ANGO) fiscal fourth quarter's top line is likely to have been driven by strong demand for its products.
AngioDynamics (ANGO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AngioDynamics (ANGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.